Key result
Autoimmune diseases frequently involve the cardiovascular system, and their pharmacological treatments can cause significant cardiovascular side effects, including heart failure and arrhythmias.
Autoimmune diseases and their pharmacological treatments significantly impact the cardiovascular system, necessitating vigilance from cardiologists to manage and prevent adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
Supports cardiologist vigilance for CV risks in autoimmune disease; leaves open optimal strategies pending prospective trials.
Cardiovascular system involvement is a frequent complication of autoimmune diseases (AD) such as systemic lupus erythematosus, scleroderma, rheumatoid arthritis, spondyloarthropaties or psoriatic arthritis. The most common forms of such involvement are pericarditis, myocarditis, accelerated atherosclerosis resulting in myocardial infarction or stroke, arrhythmias, conduction abnormalities or congestive heart failure. Some of these manifestations may be dramatic in their course and ultimately fatal. The treatment of AD may further affect the cardiovascular system and result in a lower quality of life, higher mortality and increased cost of healthcare. The aim of this review is to discuss possible cardiac complications of various AD and the related treatment of these diseases.
No takes yet. Share an insight, caveat, or question.
Jastrzębska et al. (2013) conducted a review in Autoimmune diseases. Pharmacological treatment of autoimmune diseases was evaluated. Autoimmune diseases frequently involve the cardiovascular system, and their pharmacological treatments can cause significant cardiovascular side effects, including heart failure and arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: